Journal
MOLECULAR AND CELLULAR ENDOCRINOLOGY
Volume 307, Issue 1-2, Pages 1-7Publisher
ELSEVIER IRELAND LTD
DOI: 10.1016/j.mce.2009.03.014
Keywords
Prolactin; Breast cancer; Signaling crosstalk; Targeted therapeutics
Categories
Funding
- NIH [RO1 CA78312, DK62783, K01 RR21858, T32 GM08349]
Ask authors/readers for more resources
The contributions of prolactin (PRL) to breast cancer are becoming increasingly recognized. To better understand the role for PRL in this disease, its interactions with other oncogenic growth factors and hormones must be characterized. Here, we review our current understanding of PRL crosstalk with other mammary oncogenic factors, including estrogen, epidermal growth factor (EGF) family members, and insulin-like growth factor-I (IGF-I). The ability of PRL to potentiate the actions of these targets of highly successful endocrine and molecular therapies suggests that PRL and/or its receptor (PRLR) may be an attractive therapeutic target(s). We discuss the potential benefit of PRL/PRLR-targeted therapy in combination with established therapies and implications for de novo and acquired resistance to treatment. (C) 2009 Elsevier Ireland Ltd. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available